Company intelligence / Profile preview

Innovate Voronoi

Incheon, South Koreadnb.com ↗

Ownership: Private
Development stage: Preclinical

Overview

The company has multiple programs in development, with the most advanced being in Phase 1/2 clinical trials. Their EGFR/HER2 Exon20 inhibitor (ORIC-114/VRN07) has demonstrated safety and efficacy in Phase 1 dose escalation studies for non-small cell lung cancer.

Therapeutic areas: ImmunologyOncologyDermatologyGastroenterology
Modalities: Small molecule drugs
Industry: Biotech

Drug pipeline

1 asset

ST-2286

Pre-clinical

Indications: Solid tumors

Partnerships

ORIC PharmaceuticalsJW Pharmaceuticalinno.NBrickell Biotech

Beyond the preview

Go deeper on Innovate Voronoi.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Innovate Voronoi.

Explore the full profile